Back to search results
NCT05730582

Increasing Uptake of EHR-enabled Population Health Outreach Strategies to Improve Diabetes Screening

Enrolling by Invitation
NAAges 18–75InterventionalScreening
University of Texas Southwestern Medical Center
~500,000 participants
Updated 2026-05-08 on ClinicalTrials.gov
What's tested:Parkland Diabetes Detection Program (PDDP) Screening Invitation

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Invitation efficacy
Measured over 60 days
+4 more outcomes measured

Conditions

Diabetes Mellitus, Type 2
Pre Diabetes

Explore related trials

PrediabetesType 2 Diabetes Mellitus

Where it's being run

1 sites across 1 states
Texas1

Study leadership

  • Michael Bowen, MD · PRINCIPAL_INVESTIGATOR · University of Texas Southwestern Medical Center

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patient is alive at time of data extraction
Age \>= 18 at time of data extraction and \<76
Visit with PCP at Parkland clinic in the last 18 months (548 days), where Encounter type = Virtual Visit or Encounter type = Office Visit
Patient NOT included in Parkland Diabetes Registry
Preferred language is Spanish or English
Ethnicity is Hispanic or Non-Hispanic
Race is White or Black
Patient is not pregnant in last 12 months

Exclusion

Last A1C value \<5.7 (normal)
Last A1C value \>6.4 (diabetes)
Last A1C value = blank (unchecked)
Last A1C date occurred within last 12 months from date of export
Risk score \<9
Last A1C date occurred in last 30 months from date of export
Last A1C value was \>5.7 (PDM/DM)

What this trial measures

  • Invitation efficacy60 days

    Invitation efficacy will be assessed by comparing the proportion of patients completing HgA1c or Fasting Blood Glucose screening tests at Day 60 in the targeted-tailored invitation intervention compared to the generic invitation intervention.

  • Program effectiveness12 months

    Program effectiveness will be assessed by comparing the proportion of patients completing HgA1c or Fasting Blood Glucose screening tests at Day 365 across intervention and control arms.

  • Direct costs12 months

    Direct costs of diabetes screening compared across study arms

  • Cost effectiveness as measured by costs per patient screened12 months

    Cost effectiveness will be assessed by comparing the costs per patient screened across study arms

  • Cost effectiveness as measured by cost per case found12 months

    Cost effectiveness will be assessed by comparing the costs per case found across study arms